Paul-Ehrlich-Institut

Go to:

Information on the Use of Cookies

In order to operate and optimise our website, we would like to collect and analyse statistical information completely anonymously. Will you accept the temporary use of statistics cookies?

You can revoke your consent at any time in our privacy policy.

OK

Dengue Fever Vaccines

Dengue fever vaccines protect against infection with the dengue virus.

Name De­scrip­tion Mar­ket­ing Au­tho­ri­sa­tion Hold­er Kind of Vac­cine Li­cense Num­ber Li­cense Date Further Information

Dengvaxia

Tetravalenter Dengue-Impfstoff ­(lebend, attenuiert)

Für Menschen zwischen 9 und 45 Jahren bestimmt, die in der Vergangenheit bereits mit dem Dengue-Virus infiziert waren und in Endemiegebieten leben

Sanofi Winthrop Industrie, F-94250 Gentilly

 Mono EU/1/18/1338 12.12.2018

EPAR

Qdenga

Tetravalenter Dengue-Impfstoff ­(lebend, attenuiert)

Verwendung ab einem Lebensalter von 4 Jahren / Use from 4 years of age onwards

Takeda GmbH

 Mono EU/1/22/1699 05.12.2022

EPAR: Qdenga

Disclaimer

The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.

The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.

As of: PEI announcement No. 527 in BAnz AT 12.03.2025 B3.

Summary of Product Characteristics (SmPCs) and the Package Leaflet (PL)

Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.

If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.

Updated: 14.03.2025